Resultados de la búsqueda 21-30 of 12152 for Tirzepatide

  1. Cirugía - Ensayos clínicos - Mayo Clinic

    Some patients undergoing trigger finger surgery with a pre-existing Dupuytren's cord may develop a thickened surgical scar after surgery, which can cause ...

  2. Nefrología e hipertensión - Ensayos clínicos - Mayo Clinic

    As the global epidemic of obesity and diabetes mellitus spreads, an exponential rise in incident chronic kidney disease (CKD) complicated by end stage renal ...

  3. Hematología - Ensayos clínicos - Mayo Clinic

    Scottsdale/Phoenix, Ariz., Rochester, Minn. This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies ...

  4. Cirugía - Ensayos clínicos - Mayo Clinic

    Rochester, Minn. The purpose of this study is to determine the impact of focused ultrasound (FUS) on the composition of the tumor extracellular microenvironment ...

  5. Salud de la mujer LGBTQ health - Mayo Clinic

    News. enero 2026. New study links combination of hormone therapy and tirzepatide to greater weight loss after menopause Jan. 23, 2026, 12:31 a.m. CDT.

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

  7. Deficiencia de alfa-1 antitripsina

    Learn about alpha-1 antitrypsin deficiency. American Lung Association. https://www.lung.org/lung-health-diseases/lung-disease-lookup/alpha-1-antitrypsin- ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic ...

  9. Hematología - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to assess the presence of various molecular markers in histiocytic disorders. In addition to this, to review clinical records of ...

  10. Hematología - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...